{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:56:08Z","timestamp":1793447768830,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.diabres.2025.113047","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T02:57:18Z","timestamp":1765421838000},"page":"113047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Adult-onset type 1 diabetes: early detection, differential diagnosis, and emerging disease-modifying therapies"],"prefix":"10.1016","volume":"231","author":[{"given":"Robert","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"F\u00fcchtenbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Miszon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pf\u00fctzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Reger-Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.diabres.2025.113047_b0005","first-page":"741","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"LancetDiabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.113047_b0010","doi-asserted-by":"crossref","unstructured":"Ogle GD, James S, Dabelea D, Pihoker C, Svennson J, Maniam J, et al. Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 10th edition. Diabetes research and clinical practice. 2022;183:109083.","DOI":"10.1016\/j.diabres.2021.109083"},{"issue":"Suppl 6","key":"10.1016\/j.diabres.2025.113047_b0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/dom.16402","article-title":"1 diabetes presenting in adults: Trends, diagnostic challenges and unique features","volume":"27","author":"Evans-Molina","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.diabres.2025.113047_b0020","first-page":"915","article-title":"Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium","volume":"12","author":"Magliano","year":"2024","journal-title":"LancetDiabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0025","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/dc21-1752","article-title":"The Incidence of Adult-Onset Type 1 Diabetes: a Systematic Review from 32 Countries and Regions","volume":"45","author":"Harding","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2025.113047_b0030","article-title":"Incidence of Diabetes in Children and Adolescents during the COVID-19 Pandemic: a Systematic Review and Meta-Analysis","volume":"6","author":"D'Souza","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.diabres.2025.113047_b0035","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1002\/jmv.27996","article-title":"The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: a systematic review and meta-analysis","volume":"94","author":"Rahmati","year":"2022","journal-title":"J Med Virol"},{"issue":"11","key":"10.1016\/j.diabres.2025.113047_b0040","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.2337\/dc22-0278","article-title":"The COVID-19 Pandemic Affects Seasonality, with increasing cases of New-Onset Type 1 Diabetes in Children, from the Worldwide SWEET Registry","volume":"45","author":"Reschke","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2025.113047_b0045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007732","article-title":"Genetics of type 1 diabetes","volume":"2","author":"Noble","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.diabres.2025.113047_b0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrendo.2015.218","article-title":"The role of the intestinal microbiota in type 1 diabetes mellitus","volume":"12","author":"Knip","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"10.1016\/j.diabres.2025.113047_b0055","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.2337\/db11-0364","article-title":"Genetic analysis of adult-onset autoimmune diabetes","volume":"60","author":"Howson","year":"2011","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.diabres.2025.113047_b0060","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41574-023-00853-0","article-title":"Heterogeneity and endotypes in type 1 diabetes mellitus","volume":"19","author":"Redondo","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.diabres.2025.113047_b0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2213-8587(17)30362-5","article-title":"Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank","volume":"6","author":"Thomas","year":"2018","journal-title":"The lancet Diabetes & endocrinology"},{"issue":"1","key":"10.1016\/j.diabres.2025.113047_b0070","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc08-1419","article-title":"Metabolic syndrome and autoimmune diabetes: action LADA 3","volume":"32","author":"Hawa","year":"2009","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2025.113047_b0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009088","article-title":"Can clinical features be used to differentiate type 1 from type 2 diabetes? a systematic review of the literature","volume":"5","author":"Shields","year":"2015","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.diabres.2025.113047_b0080","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2337\/dbi20-0017","article-title":"Management of Latent Autoimmune Diabetes in adults: a Consensus Statement from an International Expert Panel","volume":"69","author":"Buzzetti","year":"2020","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.diabres.2025.113047_b0085","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2337\/dc20-2834","article-title":"Latent Autoimmune Diabetes of adults (LADA) is likely to Represent a mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes","volume":"44","author":"Jones","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2025.113047_b0090","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2337\/dc21-0770","article-title":"Adult-Onset Type 1 Diabetes: Current Understanding and challenges","volume":"44","author":"Leslie","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2025.113047_b0095","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International Consensus on Risk Management of Diabetic Ketoacidosis in patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2025.113047_b0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"10.1016\/j.diabres.2025.113047_b0105","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2025.113047_b0110","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s00125-022-05836-w","article-title":"The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes","volume":"66","author":"Ferrannini","year":"2023","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.immuni.2010.04.001","article-title":"Etiology of type 1 diabetes","volume":"32","author":"Todd","year":"2010","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.diabres.2025.113047_b0120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11892-019-1235-1","article-title":"The Genetic Contribution to Type 1 Diabetes","volume":"19","author":"Bakay","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"2","key":"10.1016\/j.diabres.2025.113047_b0125","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2337\/dc18-1785","article-title":"Development and Standardization of an improved Type 1 Diabetes Genetic Risk score for use in Newborn Screening and Incident Diagnosis","volume":"42","author":"Sharp","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2025.113047_b0130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2337\/dc15-1111","article-title":"A Type 1 Diabetes Genetic Risk score can Aid Discrimination between Type 1 and Type 2 Diabetes in Young adults","volume":"39","author":"Oram","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2025.113047_b0135","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41588-021-00880-5","article-title":"Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes","volume":"53","author":"Robertson","year":"2021","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MED.0000000000000548","article-title":"The role of beta-cell dysfunction in early type 1 diabetes","volume":"27","author":"Sims","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"15","key":"10.1016\/j.diabres.2025.113047_b0145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120877","article-title":"\u03b2 Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis","volume":"3","author":"Evans-Molina","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.diabres.2025.113047_b0150","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2337\/db15-0779","article-title":"Insulitis and \u03b2-Cell Mass in the Natural history of Type 1 Diabetes","volume":"65","author":"Campbell-Thompson","year":"2016","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0155","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2337\/dc17-0806","article-title":"Type 1 Diabetes TrialNet: a Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes","volume":"41","author":"Bingley","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2025.113047_b0160","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/pedi.12029","article-title":"Clinical application of regulatory T cells in type 1 diabetes","volume":"14","author":"Marek-Trzonkowska","year":"2013","journal-title":"Pediatr Diabetes"},{"issue":"7","key":"10.1016\/j.diabres.2025.113047_b0165","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2337\/dc14-1140","article-title":"Type 1 diabetes through the life span: a position statement of the American Diabetes Association","volume":"37","author":"Chiang","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2025.113047_b0170","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/pedi.12597","article-title":"Genetics of type 1 diabetes","volume":"19","author":"Redondo","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"9","key":"10.1016\/j.diabres.2025.113047_b0175","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2337\/dc25-0192","article-title":"Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in the T1D TrialNet Pathway to Prevention Study","volume":"48","author":"Templeman","year":"2025","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.diabres.2025.113047_b0180","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2337\/dc16-2228","article-title":"Twenty-Year Progression Rate to Clinical Onset according to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-based Group of Children and Adults with a First-Degree Relative with Type 1 Diabetes","volume":"40","author":"Gorus","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.113047_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1411686","article-title":"Risk for progression to type 1 diabetes in first-degree relatives under 50 years of age","volume":"15","author":"Urrutia","year":"2024","journal-title":"Front Endocrinol"},{"issue":"12","key":"10.1016\/j.diabres.2025.113047_b0190","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.2337\/db13-0534","article-title":"GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes","volume":"62","author":"Miao","year":"2013","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.diabres.2025.113047_b0195","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1007\/s00125-021-05492-6","article-title":"Improving clinical utility of GAD65 autoantibodies by electrochemiluminescence assay and clinical phenotype when identifying autoimmune adult-onset diabetes","volume":"64","author":"Gu","year":"2021","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.diabres.2025.113047_b0200","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/dmrr.877","article-title":"Diabetes classification: grey zones, sound and smoke: Action LADA 1","volume":"24","author":"Leslie","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabres.2025.113047_b0205","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and Diabetes: a Report of a Workgroup of the American Diabetes Association and the Endocrine Society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2025.113047_b0210","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dme.12159","article-title":"The clinical utility of C-peptide measurement in the care of patients with diabetes","volume":"30","author":"Jones","year":"2013","journal-title":"Diabetic medicine : a journal of the British Diabetic Association"},{"key":"10.1016\/j.diabres.2025.113047_b0215","first-page":"200","volume":"130","author":"Fritsche","year":"2022","journal-title":"Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide\/Glucose Ratio in Selecting Glucose-Lowering Medications"},{"issue":"3","key":"10.1016\/j.diabres.2025.113047_b0220","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2337\/dc14-1952","article-title":"Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes","volume":"38","author":"Davis","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2025.113047_b0225","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2337\/db13-0881","article-title":"Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial","volume":"63","author":"Lachin","year":"2014","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.diabres.2025.113047_b0230","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaoncol.2024.3104","article-title":"Identification of Immune Checkpoint Inhibitor-Induced Diabetes","volume":"10","author":"Ruiz-Esteves","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0235","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/clinem\/dgad670","article-title":"Risk and Incidence of Endocrine Immune-Related adverse Effects under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: a Meta-Analysis of Randomized Controlled Trials","volume":"109","author":"Vardarli","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.diabres.2025.113047_b0240","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/jdi.14362","article-title":"Immune checkpoint inhibitor-related type 1 diabetes incidence, risk, and survival association","volume":"16","author":"Kamitani","year":"2025","journal-title":"J Diabetes Investig"},{"issue":"6","key":"10.1016\/j.diabres.2025.113047_b0245","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: from its Molecular Mechanisms to Clinical Practice","volume":"47","author":"Cho","year":"2023","journal-title":"Diabetes Metab J"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0250","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"issue":"7","key":"10.1016\/j.diabres.2025.113047_b0255","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2025.113047_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13030422","article-title":"Type 1 Diabetes Mellitus and Autoimmune Diseases: a critical Review of the Association and the Application of Personalized Medicine","volume":"13","author":"Popoviciu","year":"2023","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.diabres.2025.113047_b0265","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12902-019-0373-4","article-title":"Testing for type 1 diabetes autoantibodies in gestational diabetes mellitus (GDM): is it clinically useful?","volume":"19","author":"Incani","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.diabres.2025.113047_b0270","article-title":"2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142025","volume":"48(Supplement_1):S27\u2013S49","author":"Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0275","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2337\/dc06-1696","article-title":"High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes","volume":"30","author":"Buzzetti","year":"2007","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0280","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2337\/dc12-0931","article-title":"Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7","volume":"36","author":"Hawa","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.113047_b0285","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1749-6632.2002.tb02977.x","article-title":"Distinct IA-2 autoantibody epitope recognition between childhood-onset and adult-onset type 1 diabetes","volume":"958","author":"Kawasaki","year":"2002","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0290","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916934.2012.741155","article-title":"Zinc transporter type 8 autoantibodies (ZnT8A): prevalence and phenotypic associations in latent autoimmune diabetes patients and patients with adult onset type 1 diabetes","volume":"46","author":"Andersen","year":"2013","journal-title":"Autoimmunity"},{"issue":"9","key":"10.1016\/j.diabres.2025.113047_b0295","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1464-5491.2011.03272.x","article-title":"Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes","volume":"28","author":"Jones","year":"2011","journal-title":"Diabetic medicine : a journal of the British Diabetic Association"},{"issue":"12","key":"10.1016\/j.diabres.2025.113047_b0300","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s00125-023-06003-5","article-title":"High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment","volume":"66","author":"Sims","year":"2023","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.diabres.2025.113047_b0305","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2337\/dc22-1763","article-title":"Proinsulin-to-C-Peptide Ratio as a Marker of \u03b2-Cell Function in African American and European American adults","volume":"46","author":"Couch","year":"2023","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2025.113047_b0310","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12071131","article-title":"Fasting Proinsulin Independently Predicts Incident Type 2 Diabetes in the General Population","volume":"12","author":"Sokooti","year":"2022","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.diabres.2025.113047_b0315","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-2625","article-title":"Proinsulin Secretion is a Persistent Feature of Type 1 Diabetes","volume":"42","author":"Sims","year":"2019","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.diabres.2025.113047_b0320","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1111\/dom.14785","article-title":"C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective","volume":"24","author":"Maddaloni","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.diabres.2025.113047_b0325","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s001250100548","article-title":"The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes","volume":"44","author":"Wilkin","year":"2001","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.diabres.2025.113047_b0330","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diacare.26.3.832","article-title":"Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.113047_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112006","article-title":"Residual C-peptide secretion is associated with better CGM-metrics in adults with short-lasting type 1 diabetes","volume":"221","author":"Amendolara","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.diabres.2025.113047_b0340","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2337\/dc20-0567","article-title":"Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications","volume":"44","author":"Jeyam","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2025.113047_b0345","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7793","article-title":"Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes","volume":"1","author":"Long","year":"2016","journal-title":"Sci Immunol"},{"issue":"7","key":"10.1016\/j.diabres.2025.113047_b0350","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An Anti-CD3 Antibody, Teplizumab, in Relatives at risk for Type 1 Diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"issue":"583","key":"10.1016\/j.diabres.2025.113047_b0355","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"issue":"23","key":"10.1016\/j.diabres.2025.113047_b0360","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-Cell Function in newly Diagnosed Type 1 Diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N Engl J Med"},{"issue":"9789","key":"10.1016\/j.diabres.2025.113047_b0365","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.diabres.2025.113047_b0370","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2337\/dc22-2200","article-title":"Abatacept for Delay of Type 1 Diabetes Progression in stage 1 Relatives at risk: a Randomized, Double-Masked","volume":"46","author":"Russell","year":"2023","journal-title":"Controlled Trial Diabetes Care"},{"issue":"22","key":"10.1016\/j.diabres.2025.113047_b0375","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2025.113047_b0380","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/dc13-0626","article-title":"B-lymphocyte depletion with rituximab and \u03b2-cell function: two-year results","volume":"37","author":"Pescovitz","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2025.113047_b0385","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/db20-1103","article-title":"Low-Dose ATG\/GCSF in established Type 1 Diabetes: a Five-Year follow-up Report","volume":"70","author":"Lin","year":"2021","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.diabres.2025.113047_b0435","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2337\/db19-0057","article-title":"Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA(1c), and increases Regulatory to conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data","volume":"68","author":"Haller","year":"2019","journal-title":"Diabetes"},{"issue":"10510","key":"10.1016\/j.diabres.2025.113047_b0440","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(25)01674-5","article-title":"Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial","volume":"406","author":"Mathieu","year":"2025","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.diabres.2025.113047_b0390","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/s41591-024-03115-2","article-title":"Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial","volume":"30","author":"Tatovic","year":"2024","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.diabres.2025.113047_b0395","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","article-title":"Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes","volume":"383","author":"Quattrin","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.diabres.2025.113047_b0400","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","article-title":"Baricitinib and \u03b2-Cell Function in patients with New-Onset Type 1 Diabetes","volume":"389","author":"Waibel","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0445","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","article-title":"Anti-interleukin-21 antibody and liraglutide for the preservation of \u03b2-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"von Herrath","year":"2021","journal-title":"The lancet Diabetes & endocrinology"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0405","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(13)70111-6","article-title":"Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial","volume":"1","author":"Rigby","year":"2013","journal-title":"The lancet Diabetes & endocrinology"},{"issue":"8","key":"10.1016\/j.diabres.2025.113047_b0410","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1172\/JCI81722","article-title":"Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients","volume":"125","author":"Rigby","year":"2015","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.diabres.2025.113047_b0415","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2337\/db11-0955","article-title":"Preventing \u03b2-cell loss and diabetes with calcium channel blockers","volume":"61","author":"Xu","year":"2012","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.diabres.2025.113047_b0420","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2023.2064","article-title":"Effect of Verapamil on Pancreatic Beta Cell Function in newly Diagnosed Pediatric Type 1 Diabetes: a Randomized Clinical Trial","volume":"329","author":"Forlenza","year":"2023","journal-title":"J Am Med Assoc"},{"issue":"8","key":"10.1016\/j.diabres.2025.113047_b0425","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","article-title":"Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Gitelman","year":"2021","journal-title":"The lancet Diabetes & endocrinology"},{"issue":"11","key":"10.1016\/j.diabres.2025.113047_b0430","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198803173181103","article-title":"Factors associated with early remission of type I diabetes in children treated with cyclosporine","volume":"318","author":"Bougneres","year":"1988","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2025.113047_b0450","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00125-022-05823-1","article-title":"The relationship between islet autoantibody status and the genetic risk of type 1 diabetes in adult-onset type 1 diabetes","volume":"66","author":"Thomas","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2025.113047_b0455","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf304","article-title":"Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality","author":"Wei","year":"2025","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.diabres.2025.113047_b0460","doi-asserted-by":"crossref","first-page":"e3777","DOI":"10.1002\/dmrr.3777","article-title":"Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes","volume":"40","author":"Hendriks","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabres.2025.113047_b0465","article-title":"Prevalence of Islet Autoantibodies in adults without Diabetes","volume":"9(8):bvaf095","author":"Pauley","year":"2025","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.diabres.2025.113047_b0470","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12889-015-1591-y","article-title":"Global epidemiology of type 1 diabetes in young adults and adults: a systematic review","volume":"15","author":"Diaz-Valencia","year":"2015","journal-title":"BMC Public Health"},{"issue":"9","key":"10.1016\/j.diabres.2025.113047_b0475","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/dom.13788","article-title":"Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85)","volume":"21","author":"Maddaloni","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2025.113047_b0480","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2337\/dc08-2305","article-title":"Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4","volume":"33","author":"Lampasona","year":"2010","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.diabres.2025.113047_b0485","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/s41591-018-0089-4","article-title":"Verapamil and beta cell function in adults with recent-onset type 1 diabetes","volume":"24","author":"Ovalle","year":"2018","journal-title":"Nat Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725010629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725010629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:19:22Z","timestamp":1769696362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725010629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":97,"alternative-id":["S0168822725010629"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.113047","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adult-onset type 1 diabetes: early detection, differential diagnosis, and emerging disease-modifying therapies","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.113047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113047"}}